Biohaven Pharmaceutical Holding Co’s (NASDAQ:BHVN) lock-up period is set to end on Tuesday, October 31st. Biohaven Pharmaceutical Holding Co had issued 9,900,000 shares in its initial public offering on May 4th. The total size of the offering was $168,300,000 based on an initial share price of $17.00. After the end of the company’s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Several research firms have issued reports on BHVN. Zacks Investment Research upgraded Biohaven Pharmaceutical Holding Co from a “sell” rating to a “hold” rating in a research note on Friday, September 8th. BidaskClub upgraded Biohaven Pharmaceutical Holding Co from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 7th. Needham & Company LLC reiterated a “buy” rating and set a $43.00 price objective (up from $30.00) on shares of Biohaven Pharmaceutical Holding Co in a research note on Wednesday, September 13th. Piper Jaffray Companies reiterated a “buy” rating and set a $54.00 price objective on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, September 12th. Finally, Morgan Stanley increased their price objective on Biohaven Pharmaceutical Holding Co from $28.00 to $47.00 and gave the stock an “overweight” rating in a research note on Monday, September 25th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Biohaven Pharmaceutical Holding Co currently has an average rating of “Buy” and an average price target of $40.80.

COPYRIGHT VIOLATION NOTICE: “Biohaven Pharmaceutical Holding Co Ltd’s (BHVN) Lock-Up Period To End on October 31st” was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/10/24/biohaven-pharmaceutical-holding-co-ltds-bhvn-lock-up-period-to-end-on-october-31st.html.

Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN) opened at 31.16 on Tuesday. The firm’s 50-day moving average price is $35.36 and its 200 day moving average price is $28.13. Biohaven Pharmaceutical Holding Co has a 1-year low of $17.00 and a 1-year high of $39.51. The firm’s market capitalization is $1.12 billion.

Several institutional investors have recently bought and sold shares of the company. Strs Ohio acquired a new position in shares of Biohaven Pharmaceutical Holding Co during the 3rd quarter worth $680,000. Deschutes Portfolio Strategy LLC acquired a new position in shares of Biohaven Pharmaceutical Holding Co during the 3rd quarter worth $374,000. Finally, Nationwide Fund Advisors acquired a new position in shares of Biohaven Pharmaceutical Holding Co during the 3rd quarter worth $214,000.

About Biohaven Pharmaceutical Holding Co

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.